Editorial Board

Publication date: January–March 2017
Source:Alergologia Polska – Polish Journal of Allergology, Volume 4, Issue 1



The role of microbiota in allergy development

Publication date: Available online 31 March 2017
Source:Alergologia Polska – Polish Journal of Allergology
Author(s): Monika Marko, Rafał Pawliczak
The increase of allergic diseases incidence has been noticed in industrialized countries. The reason for that is sought in increasing environment pollution and hygienisation of life. Diseases including asthma, hay fever, eczema and food allergies have dramatically increased over the last century. Microbiota (intestinal microflora) is a community of microorganisms, mainly bacteria that forms in the human digestive system a complex ecosystem. Recently more and more attention is paid to the connection of intestinal microflora with the occurrence of allergic diseases. Microbiota and the beneficial effects of probiotic bacteria on human health is becoming increasingly important in allergy development. However, the importance of probiotics in the prevention of these diseases has not been proven. It is a necessity to design and carry out thorough and detailed research to confirm significance of treatment with using probiotics strains.


Prophylactic embolisation of the internal maxillary artery in patients with ankylosis of the temporomandibular joint

The aim of the present study was to assess the efficacy of using prophylactic embolisation of the internal maxillary artery to minimise the risk of bleeding during gap arthroplasty.We studied a prospective series of 14 patients with ankylosis of the temporomandibular joint (TMJ) between January 2011 and February 2016, who were under the care of one surgeon.They were all treated by embolisation of the internal maxillary artery 24hours before gap arthroplasty. The main outcome variable was estimated blood loss, and others included the need to extend the gap arthroplasty, and the risk of reankylosis.


How far reaching is our research? An analysis of the journals in which oral and maxillofacial surgery research is cited

In this study we investigate the five most cited articles in the British Journal of Oral and Maxillofacial Surgery (BJOMS). Articles cited were usually published in other OMFS journals (40%) or dentistry journals (32%). The mean (SD) SCImago Journal and Country Rank, (SJR) (an interface to access the bibliometric database of journals) for cited papers was 0.64 (SD=0.56). Nearly one third of citations were of research in OMFS and dentistry, suggesting its relevance to the wider academic community.


Compliance of referral and hospital documentation with National Institute of Health and Care Excellence guidelines for the extraction of third molars: a comparative analysis of two NHS Trusts

To find out whether documentation for the extraction of wisdom teeth complies with National Institute of Health and Care Excellence (NICE) guidelines, we reviewed the referral letters and hospital notes of patients treated at the maxillofacial unit of two NHS Trusts (A: 314 records and B: 280) over 12 months (1 September 2012 to 31 August 2013). Compliance was assessed as unsatisfactory (“indication for extraction not mentioned”, “incorrect indication”, “indication unclear”) or satisfactory (“correct indication implied”, “correct indication explicit”).


Congenital lipoma of the hard palate: case report

Congenital tumours of the oral cavity are uncommon, and most of them are teratoid. Lipoma is a benign tumour of adipose tissue commonly found in adults, and it is rare to find one that is congenital. They are most commonly found in the tongue and maxillary gingiva,1 and to the best of our knowledge, only two cases of lipoma have been reported in the hard palate (Okamoto et al and Gokul et al reported a congenital fibrolipoma and an osteolipoma that were associated with cleft palate, respectively).


The Management of Esophagogastric Cancers Enters a New Era

This timely issue of Hematology/Oncology Clinics of North America highlights the current management of cancers of the foregut (esophagus and stomach). Cancers of the esophagus and stomach remain prevalent, and together, are more common globally than cancers of the colon and rectum or hepatocellular cancer. Importantly, these cancers still carry a poor prognosis and remain a fruitful area for research and drug development. I am very proud of this issue and in particular of my friends and colleagues who were able to contribute scholarly articles that help define the disease and our care.


Mass Spectrometry to complement standardization of house dust mite and other complex allergenic extracts


In the United States, the Center for Biologics Evaluation and Research (CBER) of the US Food and Drug Administration regulates biologics used for diagnosis and treatment of allergic diseases. The Code of Federal Regulations 21CFR680.3(e) states that when measured, the potency of an allergenic extract is assessed according to its allergenic activity. As of 2016, 19 allergenic extracts are standardized for potency in the United States. While these standardized extracts constitute a minority of those available, they treat the most prevalent allergies (e.g. grass and ragweed pollens, dust mites and cat) and those that induce life-threatening anaphylaxis (e.g. Hymenoptera venom). Standardization for potency enhances safety and efficacy of immunotherapy by minimizing the risks of variations in allergen dosing when switching from one lot of manufactured extract to another, and by providing an objective measure of stability of each lot of allergenic extract over time. Allergenic extracts that have multiple immunodominant allergenic proteins are standardized with little or no information about compositional differences among extracts. Here we propose application of mass spectrometry towards measurement of compositional differences among extracts that may affect the efficacy and safety of allergen immunotherapy. In addition, we discuss of house dust mite allergen extracts as a prototypical complex extract that may be standardized by mass spectrometry.

This article is protected by copyright. All rights reserved.


Potential of a cure in patients with colorectal liver metastases and concomitant extrahepatic disease


We aimed to define the cure rate in patients with colorectal liver metastases (CRLM) and concomitant extrahepatic disease (EHD) on the 5-year disease-free survival (DFS) after surgery, and identify the factors for predicting a cure.


Patients who underwent hepatectomy for CRLM with concomitant EHD were identified. Those followed for >5 years after surgery were enrolled. A cure was defined as DFS of >5 years after the last curative surgery.


A cure was achieved in 24/175 (13%) patients (intention-to-treat [ITT] cohort), and 22/109 (19%) patients who underwent complete resection for both hepatic and extrahepatic metastases (EHD resection cohort). A multivariate analysis identified primary T1-2 (relative risk [RR] 47.4, P = 0.0001), metachronous metastasis (RR 4.9, P = 0.026), carbohydrate antigen 19-9 (CA19-9) ≤37 U/mL (RR 8.37, P = 0.015), number of liver and EHD tumors (RR 11.2, P = 0.0058), and non-incidental EHD diagnosis (RR 8.41, P = 0.018) as independent factors that predicted a cure in the ITT cohort; and primary T1-2 (RR 22.2, P = 0.013), primary N0 (RR 4.42, P = 0.031), metachronous metastasis (RR 6.48, P = 0.013), and CA19-9 ≤37 U/mL (RR 27.4, P = 0.012) in the EHD resection cohort.


Even when concomitant EHD is present, a potential of cure could be achieved with aggressive oncosurgical approach.